Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Development of a magneto-nanosensor (MNS) array for prostate cancer biomarkers

Development of a magneto-nanosensor (MNS) array for prostate cancer biomarkers

370
Gambhir, SanjivStanford University

No coordinating investigator defined.

No involved investigator sites defined.

Nanotechnology
Proteomics
G.I. and Other Associated Cancers Research Group
2

Our goal is to develop a blood-based biomarker magneto-nanosensor array for the accurate early detection and prognostication of prostate cancer

Specific Aim 1: To adapt the magneto-nanosensor array platform to the multiplex measurement of prostate cancer biomarkers for detection and progression. To accomplish this we will functionalize our magneto-nanosensor with capture antibodies for an extended panel of leading biomarker candidates for prostate cancer detection and prognostication rigorously selected from the literature. Initial experiments will be performed to evaluate the performance of the array to detect spiked samples with known quantities of biomarkers, to establish calibration curves, determine the lower limits of detection, and assess reproducibility. Once the array has been completed we will progress to evaluate it using the clinical discovery sample set described in Aim #2. Specific Aim 2: To evaluate the accuracy of the prostate cancer magneto-nanosensor array to classify clinical cancer and control specimens from the Stanford serum bank. For this aim we will test the ability of the array to accurately classify archival serum samples drawn from prostate cancer patients before and after radical prostatectomy, and from patients with positive and negative biopsies. These sera were collected by the PSA analysis laboratory in the Urology Department at the Stanford University Medical Center.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.